explore -WSS

explore

author：entertainment 2025-10-01 20:15:50 - browse：8

Gene therapy helped Conner Curran, right, walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. -- Biotech coverage from STAT — Gene therapy helped Conner Curran (at right) walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. Courtesy Jess & Chris Curran

In the beginning, Conner Curran ran up the stairs.

It was a miraculous moment for him and his parents, Jess and Chris Curran. Just months before, contractors were in their New York home to install a motorized lift, while Jess tearfully explained that it wasn’t for a grandparent but for their 7-year-old son, who suffered from Duchenne muscular dystrophy and could barely haul himself up the steps.

Then Conner was accepted as the first patient in Pfizer’s Duchenne gene therapy trial. Three weeks later, he could bound to the second floor. Soon, he could walk the two-plus miles to Goldberg’s, a local bagel shop. “I couldn’t do that before,” he told NPR in 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Liquid biopsy for lung cancer is launched by Delfi

knowledge

WSS

FDA authorizes Novavax’s updated Covid

ALS treatment from Biogen, Ionis fails in study

Colorectal cancer study finds potential in overlooked immune cell

Was Amgen transparent enough on FDA's concern on cancer drug?

Chemotherapy drug shortage eases slightly but still widespread

Supreme Court to hear if Covid misinformation is protected speech

knowledge

explore

hotspot

The high cost of giving birth even with insurance

Cherokee Nation medical school graduates its first class

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Analysis of telehealth claims data suggest service duplication

Malaria cases in Florida and Texas: Here’s what you need to know

CVS is willing to dump 10% of its Medicare Advantage members

State Dept. review finds Biden bears some blame for Afghanistan failures

HHS suspends federal funding for EcoHealth Alliance

The high cost of giving birth even with insurance

Sana to lay off nearly a third of staff, de

entertainment

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

What a koala virus tells us about the human genome

Chemotherapy drug shortage eases slightly but still widespread

When women are denied an abortion, their children fare worse than peers

AI can decode, harness the power of the humane immune system

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

entertainment

knowledge

knowledge

focus